1.Ho MW, Risk JM, Woolgar JA, Field EA, Field JK, Steele JC, et al. The clinical determinants of malignant transformation in oral epithelial dysplasia. Oral oncology. 2012;48(10):969–76.
2.Brennan M, Migliorati CA, Lockhart PB, Wray D, Al-Hashimi I, Axell T, et al. Management of oral epithelial dysplasia: a review. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2007;103 Suppl:S19 e1–2.
3.Mehanna HM, Rattay T, Smith J, McConkey CC. Treatment and follow-up of oral dysplasia - a systematic review and meta-analysis. Head & neck. 2009;31(12):1600–9.
4.Smith J, Rattay T, McConkey C, Helliwell T, Mehanna H. Biomarkers in dysplasia of the oral cavity: a systematic review. Oral oncology. 2009;45(8):647–53.
5.Nankivell P, Mehanna H. Oral dysplasia: biomarkers, treatment, and follow-up. Current oncology reports. 2011;13(2):145–52.
6.Macey R, Walsh T, Brocklehurst P, Kerr AR, Liu JL, Lingen MW, et al. Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions. Cochrane Database Syst Rev. 2015(5):CD010276.
7.Nankivell PC, Williams H, Bartlett JM, Mehanna H. Validation of tissue microarrays in oral epithelial dysplasia using a novel virtual-array technique. Journal of clinical pathology. 2012;65(12):1084–7.
8.Fan GK, Chen J, Ping F, Geng Y. Immunohistochemical analysis of P57(kip2), p53 and hsp60 expressions in premalignant and malignant oral tissues. Oral oncology. 2006;42(2):147–53.
9.Scott IS, Odell E, Chatrath P, Morris LS, Davies RJ, Vowler SL, et al. A minimally invasive immunocytochemical approach to early detection of oral squamous cell carcinoma and dysplasia. British journal of cancer. 2006;94(8):1170–5.
10.Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, et al. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer research. 2010;70(23):9742–54.
11.Rudland PS, Platt-Higgins AM, Davies LM, de Silva Rudland S, Wilson JB, Aladwani A, et al. Significance of the Fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancer. The American journal of pathology. 2010;176(6):2935–47.
12.Reed K, Ravikumar TS, Gifford RR, Grage TB. The association of Fanconi’s anemia and squamous cell carcinoma. Cancer. 1983;52(5):926–8.
13.Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nature reviews Cancer. 2011;11(7):467–80.
14.Grompe M, D’Andrea A. Fanconi anemia and DNA repair. Human molecular genetics. 2001;10(20):2253–9.
15.D’Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nature reviews Cancer. 2003;3(1):23–34.
16.Moldovan GL, D’Andrea AD. How the fanconi anemia pathway guards the genome. Annual review of genetics. 2009;43:223–49.
17.Kupfer GM. Fanconi anemia: a signal transduction and DNA repair pathway. The Yale journal of biology and medicine. 2013;86(4):491–7.
18.Tomida J, Itaya A, Shigechi T, Unno J, Uchida E, Ikura M, et al. A novel interplay between the Fanconi anemia core complex and ATR-ATRIP kinase during DNA cross-link repair. Nucleic acids research. 2013;41(14):6930–41.
19.Andreassen PR, D’Andrea AD, Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes & development. 2004;18(16):1958–63.
20.Qiao F, Mi J, Wilson JB, Zhi G, Bucheimer NR, Jones NJ, et al. Phosphorylation of fanconi anemia (FA) complementation group G protein, FANCG, at serine 7 is important for function of the FA pathway. The Journal of biological chemistry. 2004;279(44):46035–45.
21.Smogorzewska A, Matsuoka S, Vinciguerra P, McDonald ER, 3rd, Hurov KE, Luo J, et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell. 2007;129(2):289–301.
22.Bunting SF, Nussenzweig A. Dangerous liaisons: Fanconi anemia and toxic nonhomologous end joining in DNA crosslink repair. Molecular cell. 2010;39(2):164–6.
23.Muller S. Update from the 4th Edition of the World Health Organization of Head and Neck Tumours: Tumours of the Oral Cavity and Mobile Tongue. Head and neck pathology. 2017;11(1):33–40.
24.Addis MF, Tanca A, Pagnozzi D, Crobu S, Fanciulli G, Cossu-Rocca P, et al. Generation of high-quality protein extracts from formalin-fixed, paraffin-embedded tissues. Proteomics. 2009;9(15):3815–23.
25.Zhi G, Wilson JB, Chen X, Krause DS, Xiao Y, Jones NJ, et al. Fanconi anemia complementation group FANCD2 protein serine 331 phosphorylation is important for fanconi anemia pathway function and BRCA2 interaction. Cancer research. 2009;69(22):8775–83.
26.Wilson JB, Johnson MA, Stuckert AP, Trueman KL, May S, Bryant PE, et al. The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange. Carcinogenesis. 2001;22(12):1939–46.
27.Lessard JL. Two monoclonal antibodies to actin: one muscle selective and one generally reactive. Cell Motil Cytoskeleton. 1988;10(3):349–62.
28..
29.Collins NB, Wilson JB, Bush T, Thomashevski A, Roberts KJ, Jones NJ, et al. ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function. Blood. 2009;113(10):2181–90.
30.Pichierri P, Rosselli F. The DNA crosslink-induced S-phase checkpoint depends on ATR-CHK1 and ATR-NBS1-FANCD2 pathways. The EMBO journal. 2004;23(5):1178–87.
31.Geng L, Huntoon CJ, Karnitz LM. RAD18-mediated ubiquitination of PCNA activates the Fanconi anemia DNA repair network. The Journal of cell biology. 2010;191(2):249–57.
32.Wilson JB, Yamamoto K, Marriott AS, Hussain S, Sung P, Hoatlin ME, et al. FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3. Oncogene. 2008;27(26):3641–52.
33.Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. Journal of oral pathology & medicine: official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2008;37(3):127–33.
34.Nankivell P, Williams H, Matthews P, Suortamo S, Snead D, McConkey C, et al. The binary oral dysplasia grading system: validity testing and suggested improvement. Oral surgery, oral medicine, oral pathology and oral radiology. 2013;115(1):87–94.
35.Kujan O, Khattab A, Oliver RJ, Roberts SA, Thakker N, Sloan P. Why oral histopathology suffers inter-observer variability on grading oral epithelial dysplasia: an attempt to understand the sources of variation. Oral oncology. 2007;43(3):224–31.
36.Guneri P, Epstein JB. Why are we still unable to accurately determine the malignant potential or the behavior of oral mucosal lesions? Oral oncology. 2017;71:177–9.
37.Vassilakopoulou M, Parisi F, Siddiqui S, England AM, Zarella ER, Anagnostou V, et al. Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time. Laboratory investigation; a journal of technical methods and pathology. 2015;95(3):334–41.
38.Joo W, Xu G, Persky NS, Smogorzewska A, Rudge DG, Buzovetsky O, et al. Structure of the FANCI-FANCD2 complex: insights into the Fanconi anemia DNA repair pathway. Science. 2011;333(6040):312–6.
39.Moldovan GL, D’Andrea AD. FANCD2 hurdles the DNA interstrand crosslink. Cell. 2009;139(7):1222–4.
40.Gravells P, Hoh L, Solovieva S, Patil A, Dudziec E, Rennie IG, et al. Reduced FANCD2 influences spontaneous SCE and RAD51 foci formation in uveal melanoma and Fanconi anaemia. Oncogene. 2013;32(46):5338–46.
41.Nikitakis NG, Rassidakis GZ, Tasoulas J, Gkouveris I, Kamperos G, Daskalopoulos A, et al. Alterations in the expression of DNA damage response-related molecules in potentially preneoplastic oral epithelial lesions. Oral surgery, oral medicine, oral pathology and oral radiology. 2018;125(6):637–49.
42.Tsui IF, Rosin MP, Zhang L, Ng RT, Lam WL. Multiple aberrations of chromosome 3p detected in oral premalignant lesions. Cancer prevention research. 2008;1(6):424–9.
43.Shumway BS, Kresty LA, Larsen PE, Zwick JC, Lu B, Fields HW, et al. Effects of a topically applied bioadhesive berry gel on loss of heterozygosity indices in premalignant oral lesions. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008;14(8):2421–30.
44.Zhang L, Poh CF, Williams M, Laronde DM, Berean K, Gardner PJ, et al. Loss of heterozygosity (LOH) profiles—validated risk predictors for progression to oral cancer. Cancer prevention research. 2012;5(9):1081–9.
45.Marquard AM, Eklund AC, Joshi T, Krzystanek M, Favero F, Wang ZC, et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res. 2015;3:9.
46.Day RS. Planning clinically relevant biomarker validation studies using the “number needed to treat” concept. J Transl Med. 2016;14(1):117.
47.Cromwell I, Regier DA, Peacock SJ, Poh CF. Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada. Oncologist. 2016;21(9):1099–106.